SCHEMBL13290943

SCHEMBL13290943

COCCN(C)C(=O)[C@H]1CC[C@H](C(=O)Nc2c(C(=O)Nc3ccc(Cl)cn3)oc3cccnc23)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ HSD17B10 Q99714 3/20 0.39
▸ MEN1 O00255 5/20 0.39
▸ KMT2A Q03164 5/20 0.39
▸ TSHR P16473 4/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ HPGD P15428 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ F10 P00742 7/20 0.39
▸ TP53 P04637 4/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ DHODH Q02127 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ NFKB1 P19838 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13290940 0.92 SMN1; SMN2 (0.44) SMN1; SMN2HSD17B10MEN1KMT2ATSHR
SCHEMBL13290737 0.92 SMN1; SMN2 (0.44) SMN1; SMN2HSD17B10MEN1KMT2ATSHR
SCHEMBL13665001 0.90 SMN1; SMN2 (0.52) SMN1; SMN2HSD17B10MEN1KMT2ATSHR
SCHEMBL2953281 0.89 SMN1; SMN2 (0.48) SMN1; SMN2HSD17B10MEN1KMT2ATSHR
SCHEMBL2953282 0.89 SMN1; SMN2 (0.48) SMN1; SMN2HSD17B10MEN1KMT2ATSHR
SCHEMBL13290787 0.86 SMN1; SMN2 (0.36) SMN1; SMN2HSD17B10MEN1KMT2ATSHR
SCHEMBL2950971 0.85 SMN1; SMN2 (0.48) SMN1; SMN2HSD17B10MEN1KMT2ATSHR
SCHEMBL2950956 0.85 SMN1; SMN2 (0.48) SMN1; SMN2HSD17B10MEN1KMT2ATSHR
SCHEMBL13290417 0.85 SMN1; SMN2 (0.46) SMN1; SMN2HSD17B10MEN1KMT2ATSHR
SCHEMBL2949333 0.84 F10 (0.37) SMN1; SMN2HSD17B10MEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 SMN1; SMN2 4447/4885HSD17B10 943/4885MEN1 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback